iCAD is a medical technology company providing cancer detection and therapy solutions. Co.'s segments are: Cancer Detection, which includes image analysis and workflow solutions that enable healthcare personnel to identify pathologies and pinpoint prevalent cancers earlier, and various Artificial Intelligence and Computer-Aided Detection systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography; and Cancer Therapy, which provides the Xoft Axxent Electronic Brachytherapy System, an isotope-free cancer treatment platform technology for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer. The ICAD stock yearly return is shown above.
The yearly return on the ICAD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ICAD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|